$GPLB
Green Planet Bio Engineering Co. Ltd.

2023 Q2 Form 10-Q Financial Statement

#000165495423006318 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.84K $7.640K
YoY Change 30.6% -1.29%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $17.84K $7.640K
YoY Change 30.6% -1.29%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.528K -$17.84K -$7.640K
YoY Change 56.48% -230.62% -1.29%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.528K -$17.84K -$7.640K
YoY Change 56.48% 30.62% -1.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 20.01M shares 20.01M shares 20.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change
Cash & Equivalents $0.00 $0.00 $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $0.00 $0.00 $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $0.00 $0.00 $0.00
Total Long-Term Assets $0.00 $0.00
Total Assets $0.00 $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.840K
YoY Change -34.73%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $408.3K $399.8K $381.9K
YoY Change 10.8% 10.11% 9.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $408.3K $399.8K $381.9K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $399.8K $381.9K
YoY Change 10.11% 9.31%
SHAREHOLDERS EQUITY
Retained Earnings -$1.038M -$1.029M -$1.012M
YoY Change 3.7% 3.32%
Common Stock $20.01K $20.01K $629.6K
YoY Change -96.82% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$408.3K -$399.8K -$381.9K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $0.00 $0.00
YoY Change

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$8.528K -$17.84K -$7.640K
YoY Change 56.48% 30.62% -1.29%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$12.00K -$7.630K
YoY Change -354.78% -1.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $12.00K 7.630K
YoY Change 154.78% -1.42%
NET CHANGE
Cash From Operating Activities -$12.00K -7.630K
Cash From Investing Activities $0.00
Cash From Financing Activities $12.00K 7.630K
Net Change In Cash $0.00 0.000
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities -$12.00K -$7.630K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Assets Current
AssetsCurrent
0 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001392449
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20006402 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20006402 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20006402 shares
CY2023Q1 gplb Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
0
CY2022Q1 gplb Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
0
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-52622
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
GREEN PLANET BIOENGINEERING CO., LTD.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1532842
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
20807 Biscayne Blvd.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Aventura
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33180
CY2023Q1 dei City Area Code
CityAreaCode
786
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
279-2900
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20006402 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
0 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5840 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
0 usd
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
393920 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
381920 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
399760 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
381920 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20006402 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
20006 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
20006 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
609614 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
609614 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1029380 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1011540 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-399760 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-381920 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17840 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13658 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17840 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13658 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-349387 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-363045 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-381920 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17840 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-399760 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
17840 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
13658 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5840 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8948 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4710 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
12000 usd
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
4710 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4710 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported.  Actual results could differ from those estimates.  Significant items that require estimates were accruals of liabilities.</p>
CY2023Q1 gplb Working Capital Deficit
WorkingCapitalDeficit
399760 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1029380 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17840 usd
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
393920 usd
CY2023Q1 gplb Number Of Votes
NumberOfVotes
1000 integer
CY2023Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
1000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001

Files In Submission

Name View Source Status
0001654954-23-006318-index-headers.html Edgar Link pending
0001654954-23-006318-index.html Edgar Link pending
0001654954-23-006318.txt Edgar Link pending
0001654954-23-006318-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gplb-20230331.xsd Edgar Link pending
gplb_10q.htm Edgar Link pending
gplb_ex31.htm Edgar Link pending
gplb_ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gplb-20230331_cal.xml Edgar Link unprocessable
gplb-20230331_lab.xml Edgar Link unprocessable
gplb-20230331_def.xml Edgar Link unprocessable
gplb-20230331_pre.xml Edgar Link unprocessable
gplb_10q_htm.xml Edgar Link completed